FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023239847> ?p ?o ?g. }

• W2023239847 endingPage "2130" @default.
• W2023239847 startingPage "2123" @default.
• W2023239847 abstract "Measurement of carotid intima-media thickness (CIMT) has been validated as a measure of atherosclerosis and as a predictor of future cardiovascular events. Compared with glimepiride, pioglitazone has been shown to slow the progression of atherosclerosis measured by CIMT in patients with type 2 diabetes mellitus.We evaluated individual cardiovascular risk factors as predictors of the change in CIMT produced by pioglitazone treatment by determining whether their addition to a baseline model resulted in loss of significance for the treatment effect on CIMT. Pioglitazone treatment led to improvement in levels of multiple cardiovascular risk markers, including high-sensitivity C-reactive protein, apolipoprotein B, apolipoprotein A1, high-density lipoprotein (HDL) cholesterol, triglyceride, insulin, and free fatty acid. At 24 weeks, there were significant differences in HDL cholesterol, triglyceride, total cholesterol, low-density lipoprotein cholesterol, insulin, body mass index, hip circumference, and high-sensitivity C-reactive protein between the pioglitazone and glimepiride treatment groups. After adjustment for 24-week on-treatment values of cardiovascular risk factors, only inclusion of the changes in HDL cholesterol and insulin significantly impacted the magnitude and significance of the treatment effect on CIMT. Furthermore, irrespective of treatment assignment, increased HDL cholesterol at 24 weeks was a significant predictor of reduced CIMT progression at 72 weeks.The beneficial effect of pioglitazone on HDL cholesterol at 24 weeks predicted its beneficial effect for reducing CIMT progression at 72 weeks. Changes in HDL cholesterol at 24 weeks, irrespective of treatment, predicted less progression of CIMT at 72 weeks. These results suggest that suppression of atherosclerosis with pioglitazone therapy is linked to its ability to raise HDL cholesterol." @default.
• W2023239847 created "2016-06-24" @default.
• W2023239847 creator A5008079426 @default.
• W2023239847 creator A5025484561 @default.
• W2023239847 creator A5026603250 @default.
• W2023239847 creator A5027561648 @default.
• W2023239847 creator A5042492165 @default.
• W2023239847 creator A5062468141 @default.
• W2023239847 creator A5064632809 @default.
• W2023239847 creator A5066700951 @default.
• W2023239847 creator A5087631945 @default.
• W2023239847 date "2008-04-22" @default.
• W2023239847 modified "2023-09-26" @default.
• W2023239847 title "Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus" @default.
• W2023239847 cites W1585890476 @default.
• W2023239847 cites W1968973887 @default.
• W2023239847 cites W1973355122 @default.
• W2023239847 cites W1980327711 @default.
• W2023239847 cites W1990724339 @default.
• W2023239847 cites W1991934340 @default.
• W2023239847 cites W2006325480 @default.
• W2023239847 cites W2007453649 @default.
• W2023239847 cites W2008288517 @default.
• W2023239847 cites W2016183600 @default.
• W2023239847 cites W2016746678 @default.
• W2023239847 cites W2018176172 @default.
• W2023239847 cites W2020267609 @default.
• W2023239847 cites W2037449921 @default.
• W2023239847 cites W2048760408 @default.
• W2023239847 cites W2064617441 @default.
• W2023239847 cites W2079068385 @default.
• W2023239847 cites W2083281877 @default.
• W2023239847 cites W2102675827 @default.
• W2023239847 cites W2106624199 @default.
• W2023239847 cites W2115572248 @default.
• W2023239847 cites W2117092539 @default.
• W2023239847 cites W2118038095 @default.
• W2023239847 cites W2120491756 @default.
• W2023239847 cites W2123002906 @default.
• W2023239847 cites W2127125241 @default.
• W2023239847 cites W2133591735 @default.
• W2023239847 cites W2147346175 @default.
• W2023239847 cites W2149314804 @default.
• W2023239847 cites W2152084424 @default.
• W2023239847 cites W2158057499 @default.
• W2023239847 cites W2159742257 @default.
• W2023239847 cites W2159969745 @default.
• W2023239847 cites W2169033201 @default.
• W2023239847 cites W2182460401 @default.
• W2023239847 cites W2198678228 @default.
• W2023239847 cites W2316167515 @default.
• W2023239847 cites W2328529137 @default.
• W2023239847 cites W2331274940 @default.
• W2023239847 cites W3018213047 @default.
• W2023239847 cites W3021250302 @default.
• W2023239847 cites W3175417087 @default.
• W2023239847 cites W4210439574 @default.
• W2023239847 doi "https://doi.org/10.1161/circulationaha.107.746610" @default.
• W2023239847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18413496" @default.
• W2023239847 hasPublicationYear "2008" @default.
• W2023239847 type Work @default.
• W2023239847 sameAs 2023239847 @default.
• W2023239847 citedByCount "115" @default.
• W2023239847 countsByYear W20232398472012 @default.
• W2023239847 countsByYear W20232398472013 @default.
• W2023239847 countsByYear W20232398472014 @default.
• W2023239847 countsByYear W20232398472015 @default.
• W2023239847 countsByYear W20232398472016 @default.
• W2023239847 countsByYear W20232398472017 @default.
• W2023239847 countsByYear W20232398472018 @default.
• W2023239847 countsByYear W20232398472019 @default.
• W2023239847 countsByYear W20232398472020 @default.
• W2023239847 countsByYear W20232398472021 @default.
• W2023239847 countsByYear W20232398472022 @default.
• W2023239847 countsByYear W20232398472023 @default.
• W2023239847 crossrefType "journal-article" @default.
• W2023239847 hasAuthorship W2023239847A5008079426 @default.
• W2023239847 hasAuthorship W2023239847A5025484561 @default.
• W2023239847 hasAuthorship W2023239847A5026603250 @default.
• W2023239847 hasAuthorship W2023239847A5027561648 @default.
• W2023239847 hasAuthorship W2023239847A5042492165 @default.
• W2023239847 hasAuthorship W2023239847A5062468141 @default.
• W2023239847 hasAuthorship W2023239847A5064632809 @default.
• W2023239847 hasAuthorship W2023239847A5066700951 @default.
• W2023239847 hasAuthorship W2023239847A5087631945 @default.
• W2023239847 hasBestOaLocation W20232398471 @default.
• W2023239847 hasConcept C126322002 @default.
• W2023239847 hasConcept C134018914 @default.
• W2023239847 hasConcept C164705383 @default.
• W2023239847 hasConcept C2776307423 @default.
• W2023239847 hasConcept C2777180221 @default.
• W2023239847 hasConcept C2777391703 @default.
• W2023239847 hasConcept C2778163477 @default.
• W2023239847 hasConcept C2778384471 @default.
• W2023239847 hasConcept C2778913445 @default.
• W2023239847 hasConcept C2779306644 @default.
• W2023239847 hasConcept C2779339615 @default.
• W2023239847 hasConcept C2780072125 @default.

• next